
Sorrento Therapeutics SRNE
Quarterly report 2023-Q1
added 05-15-2023
Sorrento Therapeutics DPO Ratio 2011-2026 | SRNE
Annual DPO Ratio Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 907 | 824 | 714 | 917 | 3.73 K | 251 | 296 | 177 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 K | 251 | 23.1 K |
Quarterly DPO Ratio Sorrento Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 768 | 819 | - | 579 | 1.03 K | 826 | - | 834 | 1.11 K | 780 | - | 1.81 K | 2.56 K | 1.22 K | - | 202 | 389 | 268 | - | 287 | 296 | 309 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.56 K | 202 | 829 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 0.8 | -3.88 % | $ 36.6 M | ||
|
Exelixis
EXEL
|
148 | $ 46.02 | -5.5 % | $ 12.5 B | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Fortress Biotech
FBIO
|
400 | $ 2.44 | -4.49 % | $ 68.1 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.11 | 2.93 % | $ 3.66 B | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.15 | - | $ 655 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 20.83 | -13.83 % | $ 2.65 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.59 | -6.47 % | $ 423 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
30.3 | - | - | - | ||
|
Фармсинтез
LIFE
|
306 | - | - | - |